AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04119414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Like Father Like Son (LFLS) Program
Description: The LFLS Program is a private 2 90-minute session conducted by a trained CHC facilitator. The sessions will be focused on exploring issues relevant to parental decision making related to voluntary medical male circumcision (VMMC) and early infant male circumcision (EIMC). Session 1 will be conducted antenatal and Session 2 will be immediately post-partum.
Study NCT02506088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Your Voice Your View
Description: Session 1 of the intervention involves background information, an introduction to social norms, and bystander intervention skills training. Session 2 of the intervention establishes conditions for consent, types of abusive behavior and identifying abuse. Session 3 of the intervention addresses risk reduction strategies for girls. Session 3 of the intervention addresses false accusations, masculinity, and additional practice on identifying conditions for consent for boys. Session 4 of the intervention includes active practice of bystander intervention skills.
Study NCT03586154 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma
Description: combined platelet rich plasma and 1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
Study NCT03586154 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ketamine and bupivacaine injection
Description: 1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
Study NCT03586154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine and bupivacaine injection
Description: 1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
Study NCT03370471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrieval Practice + Gentle Stretching
Description: Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)
Study NCT03370471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study Only + Moderate Intensity Exercise
Description: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)
Study NCT03370471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study Only + Gentle Stretching
Description: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)
Study NCT04632472 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active fixation bipolar lead versus passive fixation quadripolar leads in Cardiac Resynchronization Therapy
Description: Cardiac resynchronization therapy trial comparing types of leads.
Study NCT04632472 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Active fixation bipolar lead versus passive fixation quadripolar leads in Cardiac Resynchronization Therapy
Description: Cardiac resynchronization therapy trial comparing types of leads.
Study NCT00004239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound 506U78
Study NCT02083666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOBI002
Description: Test Product
Study NCT02083666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Reference product
Study NCT06502899 — intervention group
Intervention type: OTHER
Intervention: Cardiac MRI
Description: Patients with a diagnosis of MINOCA and completed CMR were included in this study
Study NCT03154762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIPPV
Description: Application of chronic distension of the airway through NIPPV to produce a reduction in bronchial hyperreactivity.
Study NCT03154762 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CPAP
Description: 4 cmH2O CPAP as the minimum pressure necessary to mobilize the air flow and avoid the space death with no effect on the ventilation.
Study NCT01581541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-H71
Description: PU-H71 is a synthetic HSP90 inhibitor which can bind both open and closed conformations of HSP90. It demonstrates extended tumor retention and client protein degradation, while being rapidly cleared from normal tissues. It has shown complete tumor responses and retained sensitivity to retreatment in vivo.
Study NCT00414128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 2-3g/day for 3-6 months, in tablet, capsule or liquid form
Study NCT00414128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: intravenous cyclophosphamide, 15mg/kg with dose reductions according to age and renal function, for 3-6 months (6-10 doses total)
Study NCT02306382 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Perianal abscess drainage
Description: The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
Study NCT02306382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perianal abscess drainage
Description: The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
Study NCT02306382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D ultrasonography
Description: The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
Study NCT04117009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil 2 MG
Description: Once the participants transferred to operating room, electrocardiography, noninvasive blood pressure, pulse oximetry, and respiratory rate will be recorded. An increase or decrease from the baseline value of 30% in mean arterial pressure will be treated with iv boluses of (5 mg) ephedrine or glyceryl trinitrate (25 micg). All the participants will undergo a baseline transthoracic echocardiographic evaluation to assess the systolic and diastolic function of the left ventricle before the infusion of the study drug. Then the patients will be given oxygen by a face mask at a rate of 5-6 L/min, and Remifentanil infusion will be started using a target controlled infusion pump to reach a target plasma concentration of 2 ng/mL. Once the target concentration is reached, second echocardiographic evaluation to assess the systolic and diastolic function will be performed. Potential side effects of Remifentanil will be monitored.
Study NCT04117009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiographic evaluation
Description: Transthoracic echocardiographic examination will be performed in the spontaneously breathing patients right before the surgical procedure.
Study NCT01688856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulator
Description: The 12-week treatment period consists of two components:~1. Therapist-guided task practice performed 70 minutes twice a week in the research laboratory. If Arm+Hand CCFES or Hand CCFES, the stimulator is used during task practice.~2. Self-administered muscle stimulation exercise performed 10 sessions per week at home using the device. If Arm+Hand CCFES or Hand CCFES, each session is 46 minutes. If Arm+Hand Cyclic NMES, each session is 60 minutes.
Study NCT01688856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulator
Description: The 12-week treatment period consists of two components:~1. Therapist-guided task practice performed 70 minutes twice a week in the research laboratory. If Arm+Hand CCFES or Hand CCFES, the stimulator is used during task practice.~2. Self-administered muscle stimulation exercise performed 10 sessions per week at home using the device. If Arm+Hand CCFES or Hand CCFES, each session is 46 minutes. If Arm+Hand Cyclic NMES, each session is 60 minutes.
Study NCT00253877 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complication rate
Description: All patients in the active comparator group received the Conserve Plus Hip Resurfacing System, manufactured by Wright Medical Technology. The complication rate and clinical efficacy will be recorded and compared to the Total Hip Replacement historical control group.
Study NCT00253877 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Complication rate
Description: All patients in the active comparator group received the Conserve Plus Hip Resurfacing System, manufactured by Wright Medical Technology. The complication rate and clinical efficacy will be recorded and compared to the Total Hip Replacement historical control group.
Study NCT02592512 — intervention group
Intervention type: OTHER
Intervention: NIV-NAVA
Description: Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
Study NCT02592512 — intervention group
Intervention type: OTHER
Intervention: NIV-PS/PC
Description: Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
Study NCT00972777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifloxacin
Description: Besifloxacin 0.6% administered into the study eye two times a day for three days.
Study NCT00972777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (Placebo)
Description: Vehicle administered to the study eye two times a day for three days.
Study NCT00654342 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intraoperative injection (in vivo)
Description: Intraoperative injection
Study NCT00654342 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Postoperative injection (ex vivo)
Description: postoperative injection
Study NCT06000020 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic appendectomy
Description: Laparoscopic appendectomy as performed as standard world wide. Division of the appendix with laparoscopic stapler.
Study NCT03933774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tretinoin 0.05% cream
Description: Stieva-A Cream 0.05%, 25g, GSK
Study NCT03933774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% cream
Description: Stieva-A Cream 0.05%, 25g, GSK
Study NCT03933774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Physiogel Daily Mositure Therapy Facial cream, 150mL, Stiefel
Study NCT03933774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo cream
Description: Physiogel Daily Mositure Therapy Facial cream, 150mL, Stiefel
Study NCT00803270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-Surgical Intervention
Description: Both oral urge incontinence medication and behavioral treatment
Study NCT00803270 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical
Description: Initial surgical (stress incontinence surgery) treatment approach.
Study NCT04445181 — intervention group
Intervention type: DRUG
Intervention: The physician's prescription in routine clinical practice
Description: This is an Observational study that will not involve prescription of the drugs.
Study NCT00541723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin)
Description: Intramuscular injection at day 0, at 3 and 4 injection sites per eye (4 x 3 or 3 x 4 units = 12 units per eye)
Study NCT00541723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection at day 0, at 3 and 4 injection sites per eye.
Study NCT03628365 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMB (beta-hydroxy beta-methylbutyrate)
Description: 1.5 g, b.i.d., by the enteral route, from Day 4 to Day 30 (minimum 10 days)
Study NCT03628365 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: HMB (beta-hydroxy beta-methylbutyrate)
Description: 1.5 g, b.i.d., by the enteral route, from Day 4 to Day 30 (minimum 10 days)
Study NCT05767671 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-Bronchoscopic Mini Bronchoalveolar Lavage
Description: A minimally invasive technique frequently used in the ICU to obtain alveolar fluid samples from mechanically ventilated patients. The technique uses a commercially available telescoping catheter with a curved distal tip that allows the operator to direct the catheter into the right or left lung. The catheter is passed through an air-tight adapter on the distal end of the endotracheal tube and gently advanced to the desired lung until resistance is encountered. The inner catheter is then advanced until resistance is again encountered, signifying that the distal catheter tip is wedged. 20ml of sterile saline is instilled into the catheter followed by 5 ml of air, and the fluid aspirated. Two additional 20ml aliquots of sterile saline are injected and aspirated in a similar fashion. Specimens are pooled and on average provide a combined volume of 10ml.
Study NCT03502954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABY-039
Description: ABY-039
Study NCT03502954 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02832700 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein glycomacropeptide
Study NCT02832700 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04527120 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: indigenously developed ultrasound phantom (IDUP)
Description: Ultrasound phantom model developed in the department of Emergency Medicine of Jubilee Mission Medical College, to train vascular access.
Study NCT02842892 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tissue stiffness
Study NCT03408782 — intervention group
Intervention type: PROCEDURE
Intervention: Insertion of drainage
Study NCT03787225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-0833
Description: Participants will receive dose levels of 0.3, 0.9 or 1.8 mg of NNC0174-0833 subcutaneously. Each participant will receive only one dose.
Study NCT03787225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0174-0833)
Description: Participants will receive NNC0174-0833 matched placebo subcutaneously.
Study NCT02272049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 129 Xenon
Description: During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
Study NCT01670123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Real-Time Intervention for Stabilizing Mood
Description: Interactive mobile web-based behavioral intervention targeting symptoms of bipolar disorder
Study NCT01670123 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Personalized Real-Time Intervention for Stabilizing Mood
Description: Interactive mobile web-based behavioral intervention targeting symptoms of bipolar disorder
Study NCT03351166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY85-3934)
Description: Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
Study NCT00909454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2000 IU Vitamin D3 daily supplement
Description: 2000 IU vitamin D3 supplement to be taken once daily over 4 months
Study NCT00909454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 400 IU Vitamin D3 supplement
Description: 400 IU Vitamin D3 supplement to be taken daily over 4 months
Study NCT00639223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Yeast Rice
Description: Four 600mg capsules twice daily for 12 weeks
Study NCT00639223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: One 20mg capsule twice daily for 12 weeks
Study NCT00639223 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification program
Description: Weekly sessions each lasting 3 1/2 hours for 12 weeks
Study NCT00639223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program
Description: Weekly sessions each lasting 3 1/2 hours for 12 weeks
Study NCT00521742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 15 mg to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 52 weeks.
Study NCT00521742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Glyburide 2.5 mg to 15 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
Study NCT00521742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 15 mg or 30 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally once daily for up to 52 weeks.
Study NCT00521742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Glyburide 5 mg or 10 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally once daily for up to 52 weeks.
Study NCT03726762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBs at the end of the main meal + weight control program
Description: Subjects are asked to have 250 ml DBs at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan.
Study NCT03726762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water at the end of the main meal+ weight control program
Description: Subjects are asked to have 250 ml water at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan.
Study NCT02921269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT02921269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT02921269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00984035 — intervention group
Intervention type: OTHER
Intervention: urine samples (biomarkers)
Description: Urine samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
Study NCT00984035 — intervention group
Intervention type: OTHER
Intervention: blood samples (biomarkers)
Description: blood samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
Study NCT00984035 — intervention group
Intervention type: OTHER
Intervention: blood sample (DNA)
Description: Blood sample collected for DNA analysis at anytime while on-study.
Study NCT01475552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Description: Patients, who showed PRU >270 unit and were randomized to abciximab group,were treated with abciximab in addition to conventional antiplatelet treatment (aspirin+clopidogrel).
Study NCT01475552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Patients,who showed PRU >270 unit and were randomized to control group,were treated with conventional antiplatelet therapy (aspirin+clopidogrel) during PCI and follow up periods.~Aspirin : D-1 300mg, D0-30 100mg qd Clopidogrel : D-1 300mg, D0-30 75mg qd
Study NCT01088100 — intervention group
Intervention type: GENETIC
Intervention: Genotyping
Description: Determination of 3 types of clock gene genotypes (HPER 4/4, 5/4, 5/5) on all blood samples
Study NCT01419041 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: crizotinib
Description: Single-dose oral 250 mg crizotinib in subjects with normal renal function (CLcr =>90 mL/min)
Study NCT01419041 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: crizotinib
Description: Single-dose oral 250 mg crizotinib in subjects with severe renal impairment (CLcr \<30 mL/min)
Study NCT01920386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol hydrochloride/Acetaminophen Tab.
Study NCT01920386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride/Acetaminophen SR Tab.
Study NCT04515069 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional technique of tooth preparation
Description: Depth cutter wheels of predetermined depths (Komet, Germany) were used to perform the preparation directly on the tooth structure.~Depth cuts were performed on the labial surface using depth cutter wheels (Komet, Germany) with radius of 0.3 mm and 0.5 mm which is directly related to the thickness of the laminate veneers in the cervical and incisal one thirds respectively. Then islands of tooth structure between depth orientation grooves were removed.~Proximal reduction:~The interproximal reduction was completed just labial to the contact areas using a round end tapered diamond stone (Mani, Japan), and polishing was performed using polishing strips (Sof-Lex, 3M ESPE, Seefeld, Germany).~Incisal reduction:~Vertical depth grooves were created. Then, the round end tapered diamond stone (Mani, Japan)was used to create 1.5 mm incisal butt joint preparation.~Then, finishing and polishing of tooth preparation was performed.